This site is intended for healthcare professionals
Guidelines
  • Home
  • /
  • Guidelines
  • /
  • Hidradenitis suppurativa
  • /
  • Joint AAD-HSF guidelines of care for the managemen...
Guideline

Joint AAD-HSF guidelines of care for the management of hidradenitis suppurativa

Read time: 1 mins
Last updated: 20th Oct 2026
Availability: Free full text
Status: Current
Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa


Background: Hidradenitis suppurativa affects 0.7% to 1.5% of the global population and causes substantial disability and meaningfully impairs quality of life.

Objective: To provide evidence-based recommendations for the management of hidradenitis suppurativa.

Methods: A workgroup conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach to assess the certainty of evidence and to develop recommendations.

Results: This guideline presents 37 evidence-based recommendations. Strong recommendations are made for adalimumab, bimekizumab, infliximab, secukinumab, and routine pain assessment. Conditional recommendations are made for topical clindamycin, resorcinol, and ruxolitinib; oral doxycycline, tetracycline, and clindamycin with rifampin; intravenous ertapenem; spironolactone; short-term systemic corticosteroids; upadacitinib; specific procedural interventions; tobacco cessation; supportive pain management; and zinc supplementation and vitamin D repletion.

Limitations: Analysis is limited to best evidence available from systematic review.

Conclusions: These guidelines provide evidence-based recommendations for the management of hidradenitis suppurativa.


Read full Guideline